With the goal to test the efficacy of this combination in an MCL xenograft, we found in vitro (i) that LR was more active than Moxe against MCL cells and that (ii) MCL cells had to be exposed to CD22-targeting rITs for a highly variable time for them to die. The gene discussed is CD22; the disease is mantle cell lymphoma.